Anti-TNF alpha therapy, lipid profile and carotid intimal thickness [11]

Rheumatology

Volumn 46, Issue 10, 2007, Pages 1626-

  Armstrong, D J ^a  

^a UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; METHOTREXATE; NITRIC OXIDE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA; ATHEROSCLEROSIS; CAROTID ARTERY; DOWN REGULATION; DRUG CHOICE; DRUG RESPONSE; HUMAN; LETTER; LIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN METABOLISM; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CAROTID ARTERY, COMMON; HUMANS; LIPIDS; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA;

EID: 34848897860     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem194     Document Type: Letter

References (3)

1. Del Porto F, Lagana B, Lai S et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007;20[Epub ahead of print].
2. Spanakis E, Sidiropoulos P, Papadakis J et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-6.
3. McCarey DW, McInnes IB, Madhok R. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.